期刊文献+

紫杉醇、卡铂和顺铂对裸鼠荷人卵巢癌移植瘤抑瘤效果的实验研究

Etudy of the efficacy of taxol,carboplatin and cisplatin on the human ovarian carcinoma xenografts in BALB/c-nu mice
下载PDF
导出
摘要 目的:观察紫杉醇、卡铂和顺铂对裸鼠荷人卵巢癌移植瘤的抑瘤效果。方法:选取2例本实验室已建立的裸鼠荷人卵巢癌移植瘤模型(模型1和模型2)分别给予生理盐水、紫杉醇、卡铂和顺铂,动态测量各组移植瘤体积,药物的抑瘤效果以肿瘤的相对增殖率表示。结果:模型1和模型2的移植瘤生长速度不同,二者分别于接种后第7天和第3周移植瘤体积均值超过100 mm3。紫杉醇、卡铂和顺铂均可显著抑制模型1和模型2移植瘤的生长(P均<0.001)。处死裸鼠时,3种药物对模型1和模型2的肿瘤相对增殖率分别为44.93%、27.1%、11.77%和49.50%、28.97%、6.79%。结论:紫杉醇、卡铂和顺铂单一使用时在实验周期内对人卵巢癌裸鼠移植瘤均有很好的抑瘤效果,可以应用裸鼠荷人卵巢癌移植瘤模型研发新药。 Objective: To test the efficacy of taxol,carboplatin and cisplatin on the human ovarian carcinoma xenografts.Methods: The P5 xenografts of model 1 and model 2 were randomly devided into 4 groups(blank controller,taxol,carboplatin,and cisplatin),respectively.The efficacies of the above drugs were evaluated by relative proliferation rate.Results: The growth speed of model 1 and model 2 was different.The average volume of the xenografts reached 100 mm3 at 7 days and 3 weeks after inoculation,respectively.Taxol,carboplatin and cisplatin could slow down the growth rate of the xenografts originated from model 1and model 2 significantly.The relative growth rate of model 1 were 44.93%,27.1% and 11.77% in taxol,carboplatin,and cisplatin group,respectively.Correspondingly,those of model 2 were 49.50%,28.97%,6.79%,respectively.Conclusion: All the three drugs have anticancer activity to the human ovarian carcinoma xenografts in BALB/c-nu mice in the experiment period.It's helpful to develop new anticancer drugs.
出处 《天津医科大学学报》 2012年第3期306-308,共3页 Journal of Tianjin Medical University
关键词 裸鼠移植瘤 卵巢癌 紫杉醇 卡铂 顺铂 xenografts in nude mice ovarian carcinoma taxol carboplatin cisplatin
  • 相关文献

参考文献2

二级参考文献35

  • 1Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2- neu mRNA expression in non-small cell lung cancer is correlated with survival [J]. Clin Cancer Res, 2001,7(7):1850-1855.
  • 2Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor- related growth factors and receptors and of neoangiogenesis in completely resected stage I -IIIA non- small- cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival [J]. Clin Cancer Res, 1998,4(1):241-249.
  • 3Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression [J]. Clin Cancer Res, 1997,3(4):515-522.
  • 4Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors [J]. Semin Oncol, 2003,30(1 Suppl 1):3-11.
  • 5Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non -small- cell lung cancer (FLEX): an open- label randomised phase III trial [J]. Lancet, 2009,373(9674):1525-1531.
  • 6Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first- line therapy for patients with advanced or metastatic non small- cell lung cancer [J]. J Clin Oncol, 2007,25(36):5777-5784.
  • 7Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first- line therapy in EGFR-expressing advanced non -small- cell lung cancer [J]. Ann Oncol, 2008,19(2):362-369.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Multi- institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small- cell lung cancer (The IDEAL 1 Trial) [J]. J Clin Oncol, 2003,21(12):2237-2246.
  • 9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non -small cell lung cancer: a randomized trial [J]. JAMA, 2003,290 (16):2149 - 2158.
  • 10Niho S, Kubota K, Goto K, et al. First- line single agent treatment with gefitinib in patients with advanced non-small- cell lung cancer: a phase II study [J]. J Clin Oncol, 2006,24(1): 64-69.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部